| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ARHGDIA; GDIA1; Rho GDP-dissociation inhibitor 1; Rho GDI 1; Rho-GDI alpha |
| Entrez GeneID | 396 |
| WB Predicted band size | Calculated MW: 23 kDa; Observed MW: 26 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human RhoGDI |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于RhoGDI抗体的3篇假想参考文献(基于常见研究领域构造，非真实文献)：
1. **文献名称**：*RhoGDI regulates cell migration and invasion by modulating Rac1 activity in breast cancer*
**作者**：Chen L, et al.
**摘要**：本研究利用RhoGDI特异性抗体，通过Western blot和免疫荧光技术，揭示了RhoGDI在乳腺癌细胞中通过抑制Rac1的活化调控细胞迁移和侵袭的机制，并发现其低表达与患者预后不良相关。
2. **文献名称**：*Immunohistochemical analysis of RhoGDI expression in Alzheimer's disease brain tissues*
**作者**：Saito T, et al.
**摘要**：通过开发高特异性RhoGDI抗体，作者发现阿尔茨海默病患者脑组织中RhoGDI表达显著降低，提示其可能通过影响神经元细胞骨架稳定性参与疾病进展。
3. **文献名称**：*RhoGDI as a potential biomarker in colorectal cancer: Antibody-based detection and clinical correlation*
**作者**：Müller R, et al.
**摘要**：该研究采用新型RhoGDI单克隆抗体对结直肠癌组织进行检测，发现RhoGDI高表达与肿瘤转移和化疗耐药性相关，提示其可作为治疗靶点或预后标志物。
4. **文献名称**：*Interaction of RhoGDI with oncogenic Ras: Insights from co-immunoprecipitation assays*
**作者**：Harper ME, et al.
**摘要**：通过RhoGDI抗体进行免疫共沉淀实验，揭示了RhoGDI与Ras蛋白的相互作用在肿瘤细胞异常增殖中的调控作用，为靶向RhoGDI-Ras通路提供了实验依据。
---
注：以上文献为示例性质，实际引用时需查询真实数据库(如PubMed)获取准确信息。
RhoGDI (Rho GDP-dissociation inhibitor) antibodies are essential tools for studying the regulation and function of Rho GTPases, a subfamily of small signaling proteins involved in cytoskeletal dynamics, cell motility, and gene expression. RhoGDIs act as critical regulators by binding to inactive Rho GTPases (GDP-bound form), sequestering them in the cytoplasm, and preventing their premature activation or degradation. Dysregulation of RhoGDI-mediated pathways has been linked to cancer metastasis, neurological disorders, and immune dysfunctions, making these proteins significant targets for biomedical research.
RhoGDI antibodies are specifically designed to detect RhoGDI isoforms (e.g., RhoGDIα, RhoGDIβ) in experimental applications such as Western blotting, immunohistochemistry, and immunoprecipitation. They enable researchers to investigate protein expression levels, subcellular localization, and interactions with Rho GTPases under various physiological or pathological conditions. For instance, elevated RhoGDIα expression has been observed in certain cancers, suggesting its role as a potential biomarker or therapeutic target.
These antibodies are typically validated for specificity and sensitivity across species, particularly human, mouse, and rat models. Their development and optimization have advanced studies on Rho GTPase signaling networks, offering insights into cell signaling mechanisms and disease pathogenesis. By facilitating precise detection of RhoGDI proteins, these antibodies remain indispensable in both basic research and drug discovery pipelines.
×
